NG101

DRUG2 trials

Sponsors

Neurogastrx, Inc.

Conditions

Diabetic GastroparesisHealthyIdiopathic GastroparesisOverweight and Obesity

Phase 2

A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants With Symptomatic Diabetic or Idiopathic Gastroparesis

CompletedNCT04303195

Neurogastrx, Inc.Diabetic Gastroparesis, Idiopathic Gastroparesis

Start: 2020-08-01End: 2023-02-25Updated: 2025-08-28

A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a Glucagon-like Peptide-1 (GLP-1) Agonist

CompletedNCT06500429

Neurogastrx, Inc.Healthy, Overweight and Obesity

Start: 2024-06-24End: 2024-09-13Updated: 2025-09-04